Added to YB: 2025-09-22
Pitch date: 2025-06-30
VERA [bullish]
Vera Therapeutics, Inc.
+70.77%
current return
Author Info
No bio for this author
Company Info
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Market Cap
$3.0B
Pitch Price
$23.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.62
P/E
-7.62
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Platinum International Health Sciences Fund Portfolio Holding: Vera Therapeutics, Inc.
VERA added to position: B cell modulator showed significant proteinuria reduction in IgAN despite recent weakness from Otsuka competition. Atacicept (anti-BAFF/APRIL) positioned for success in growing nascent indication. Long-term eGFR stabilization data & dual BAFF/APRIL inhibition key differentiators.
Read full article (1 min)